IN THE MEDIA

Strand Therapeutics targeting solid tumors with with its MIT born technology

Strand Therapeutics on its Bristol-Myers Squibb LabCentral Golden Ticket Win

Forbes

From Here To Cured: What Will Post-Pandemic Biotech Look Like?

In Vivo

Lessons From Biotech Entrepreneurs: Pitching Your First-In-Class Innovation

OZY

The Man Delivering Covid Vaccines to Poorer Nations

BioSpace

Strand Therapeutics’ mRNA Logic Circuits Enhance Gene Therapy’s Safety, Ease and Controllability

Medium

Becoming a Post-Pandemic Species

The Coronavirus Pandemic

Coronavirus: in search for vaccine, US small firms take a leading role

Med City News

Among Covid-19 vaccine technologies, mRNA represents faster, easier approach, some experts say

Merger Market

Global biotech and pharma leverage pipelines for COVID-19, but no quick win solutions - Analysis

Business Wire

Dr. Dane Wittrup & Dr. Mark Frohlich Join Strands Advisory Board

MIT Technology Review

A coronavirus vaccine will take at least 18 months—if it works at all

Medium

Strand Therapeutics — Genetically Programming mRNA

Boston Business Journal

MIT gene-therapy spinout raises $6M

Bloomberg

$6 Million Seed Financing to Advance its Programmable mRNA

FinSME

Strand Therapeutics Raises $6M in Seed Funding

BIOCENTURY

Strand’s smart mRNA

Fierce Biotech

Improving cancer immunotherapy by controlling RNA expression

GEN Edge

RNA-Based Gene Therapy Can Be Turned ON or OFF via Synbio Switches

MIT News

This RNA-based technique could make gene therapy more effective